Research Topics
| Amy S ChappellSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjectsS S Jhee
California Clinical Trials Medical Group, Inc, 1509 Wilson Terrace, 55 Wing Main Floor, Glendale, CA 91206-4007, USA
J Clin Pharmacol 46:424-32. 2006..LY450108 and LY451395 1 mg and 5 mg were measured in the CSF. Single and multiple oral doses of LY450108 and LY451395 were determined to be safe and well tolerated in healthy subjects...
Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trialAmy S Chappell
Lilly Research Laboratories, Indianapolis, IN, USA
Pain 146:253-60. 2009..Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo)...
Effect of duloxetine in patients with fibromyalgia: tiredness subgroupsLaurence A Bradley
Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama 35294, USA
Arthritis Res Ther 12:R141. 2010..This study tested the hypothesis that baseline ratings of fatigue/tiredness would be negatively associated with the efficacy of duloxetine on measures of pain and functional ability in patients with fibromyalgia...- A crossover, add-on trial of talampanel in patients with refractory partial seizuresA S Chappell
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Neurology 58:1680-2. 2002..001) with a median seizure reduction of 21%. Eighty percent of patients had fewer seizures on talampanel than on placebo. Dizziness (52%) and ataxia (26%) were the only significant adverse events... - A 1-year safety and efficacy study of duloxetine in patients with fibromyalgiaAmy S Chappell
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
Clin J Pain 25:365-75. 2009..Evaluate the efficacy and safety of duloxetine at doses up to 120 mg once daily in patients with fibromyalgia... - AMPA potentiator treatment of cognitive deficits in Alzheimer diseaseA S Chappell
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Neurology 68:1008-12. 2007..To investigate the efficacy and safety of the positive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid modulator LY451395 in patients with mild to moderate Alzheimer disease (AD) (Mini-Mental State Examination scores 14 to 26)... - Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded studyVladimir Skljarevski
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Pain Med 11:648-57. 2010..To assess the maintenance of the effect of duloxetine in the treatment of chronic low back pain... - A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the kneeAmy S Chappell
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Pain Pract 11:33-41. 2011..To evaluate the efficacy and safety of duloxetine in the treatment of chronic pain due to osteoarthritis of the knee... - Efficacy and safety of duloxetine in patients with chronic low back painVladimir Skljarevski
Lilly Research Laboratories, Indianapolis, IN, USA
Spine (Phila Pa 1976) 35:E578-85. 2010..This was a randomized, double-blind, placebo-controlled clinical trial... - An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic painJoachim F Wernicke
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Pain Med 8:503-13. 2007..To assess the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks, and compare duloxetine with routine care in the management of patients with diabetic peripheral neuropathic pain (DPNP)... - Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic painVladimir Skljarevski
Eli Lilly and Company, Indianapolis, Indiana, USA
Diabetes Metab Res Rev 25:623-31. 2009..To evaluate the maintenance of effect of duloxetine 60 mg QD over 26 weeks in patients with diabetic peripheral neuropathic pain (DPNP)... - Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritisMadelaine M Wohlreich
correspondence and M D, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4103, Indianapolis, IN 46285, USA
Psychosomatics 50:402-12. 2009.... - A phase II trial of talampanel in subjects with amyotrophic lateral sclerosisRobert M Pascuzzi
Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Amyotroph Lateral Scler 11:266-71. 2010..These findings provide strong support for a phase III trial to determine the efficacy of talampanel in subjects with ALS... - A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgiaAmy S Chappell
Lilly Research Laboratories, Indianapolis, IN, USA
Int J Gen Med 1:91-102. 2009..Assess the efficacy of duloxetine 60/120 mg (N = 162) once daily compared with placebo (N = 168) in the treatment of patients with fibromyalgia, during six months of treatment... - LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraineC N Sang
Massachusetts General Hospital, Boston, USA
Cephalalgia 24:596-602. 2004..Larger trials are needed to further test the hypothesis...